skip to Main Content

Copenhagen based Biotech company providing second to none assays and complexes within the molecular immunology space serving more than 70 biotech / pharma research institutes worldwide. Raised €3.5 Million in a Seed round to facilitate development of their cancer prediction tool using Immunitrack Neoscreen™ technology. Contact CEO Stephen
Thorgrimson PhD (sthor@immuitrack.com)

Immunitrack
Back To Top